{"denoms":[{"counts":[{"groupId":"BG000","value":"15"}],"units":"Participants"}],"groups":[{"description":"Participants were accrued at 50 mg/m\\^2 dose level after December 30, 2009 addendum. Participants to receive 50 mg/m\\^2 dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Phase II"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"55","upperLimit":"81","value":"64"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Singapore"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"A total of sixteen participants were accrued to the 50 mg/m\\^2 after the December 30, 2009 amendment (6 at MTD plus 10 phase II) and were grouped together as Phase II. Of these 16 particpants, one participant was excluded due to a major treatment violation."}